Advertisement

Investigational New Drugs

, Volume 30, Issue 3, pp 1244–1247 | Cite as

Everolimus-related organizing pneumonia: a report establishing causality

  • Justine Frija
  • Dominique Joly
  • Bertrand Knebelmann
  • Daniel Dusser
  • Pierre-Régis Burgel
SHORT REPORT

Introduction

Everolimus (RAD001) is an oral mTOR inhibitor that belongs to the group of proliferation signal inhibitors (PSI), which also includes sirolimus and temsirolimus. These compounds have antiproliferative and antifibrotic properties, and were initially used as immunosuppressants in solid organ transplantation. Their pleiotropic effects led to their use in cancer therapy. Drug-related pneumonias were first described in subjects treated with sirolimus [1], but subsequent reports suggested that everolimus could also cause pneumonia [2, 3, 4, 5, 6]. However, all cases of everolimus-related pneumonia have been reported in subjects (i.e. transplant recipients or subjects with advanced cancers), who had received multiple therapies or who had pre-existing pulmonary disease (e.g. lung cancer). This has led to difficulties in establishing a firm causal relationship. We report a case of everolimus-related organizing pneumonia in a subject without pre-existing pulmonary disease or...

Keywords

Everolimus Sirolimus Ramipril Autosomal Dominant Polycystic Kidney Disease Temsirolimus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Morelon E, Stern M, Israel-Biet D, Correas JM, Danel C, Mamzer-Bruneel MF, Peraldi MN, Kreis H (2001) Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients. Transplantation 72:787–790PubMedCrossRefGoogle Scholar
  2. 2.
    David S, Kumpers P, Shin H, Haller H, Fliser D (2007) Everolimus-associated interstitial pneumonitis in a patient with a heart transplant. Nephrol Dial Transplant 22:3363–3364PubMedCrossRefGoogle Scholar
  3. 3.
    Alexandru S, Ortiz A, Baldovi S, Milicua JM, Ruiz-Escribano E, Egido J, Plaza JJ (2008) Severe everolimus-associated pneumonitis in a renal transplant recipient. Nephrol Dial Transplant 23:3353–3355PubMedCrossRefGoogle Scholar
  4. 4.
    Otton J, Hayward CS, Keogh AM, Glanville AR, Macdonald PS (2009) Everolimus-associated pneumonitis in 3 heart transplant recipients. J Heart Lung Transplant 28:104–106PubMedCrossRefGoogle Scholar
  5. 5.
    White DA, Schwartz LH, Dimitrijevic S, Scala LD, Hayes W, Gross SH (2009) Characterization of pneumonitis in patients with advanced non-small cell lung cancer treated with everolimus (RAD001). J Thorac Oncol 4:1357–1363PubMedCrossRefGoogle Scholar
  6. 6.
    Schrader J, Sterneck M, Klose H, Lohse AW, Nashan B, Fischer L (2010) Everolimus-induced pneumonitis: report of the first case in a liver transplant recipient and review of treatment options. Transpl Int 23:110–113PubMedCrossRefGoogle Scholar
  7. 7.
    Walz G, Budde K, Mannaa M, Nurnberger J, Wanner C, Sommerer C, Kunzendorf U, Banas B, Horl WH, Obermuller N, Arns W, Pavenstadt H, Gaedeke J, Buchert M, May C, Gschaidmeier H, Kramer S, Eckardt KU (2010) Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med 363:830–840Google Scholar
  8. 8.
    Camus P, Fanton A, Bonniaud P, Camus C, Foucher P (2004) Interstitial lung disease induced by drugs and radiation. Respiration 71:301–326PubMedCrossRefGoogle Scholar
  9. 9.
    Rodriguez-Moreno A, Ridao N, Garcia-Ledesma P, Calvo N, Perez-Flores I, Marques M, Barrientos A, Sanchez-Fructuoso AI (2009) Sirolimus and everolimus induced pneumonitis in adult renal allograft recipients: experience in a center. Transplant Proc 41:2163–2165PubMedCrossRefGoogle Scholar
  10. 10.
    Ellard SL, Clemons M, Gelmon KA, Norris B, Kennecke H, Chia S, Pritchard K, Eisen A, Vandenberg T, Taylor M, Sauerbrei E, Mishaeli M, Huntsman D, Walsh W, Olivo M, McIntosh L, Seymour L (2009) Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol 27:4536–4541PubMedCrossRefGoogle Scholar
  11. 11.
    O’Donnell A, Faivre S, Burris HA 3rd, Rea D, Papadimitrakopoulou V, Shand N, Lane HA, Hazell K, Zoellner U, Kovarik JM, Brock C, Jones S, Raymond E, Judson I (2008) Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 26:1588–1595PubMedCrossRefGoogle Scholar
  12. 12.
    Montagnino G, Sandrini S, Casciani C, Schena FP, Carmellini M, Civati G, Rigotti P, Cossu M, Altieri P, Salvadori M, Federico S, Stefoni S, Cambi V, Albertazzi A, Buoncristiani U, Berloco P, Segoloni G, Boschiero L, Sparacino V, Donati D, Turello E, Dal Canton A, Ponticelli C (2005) A randomized trial of steroid avoidance in renal transplant patients treated with everolimus and cyclosporine. Transplant Proc 37:788PubMedCrossRefGoogle Scholar
  13. 13.
    Cordier JF (2006) Cryptogenic organising pneumonia. Eur Respir J 28:422–446PubMedCrossRefGoogle Scholar
  14. 14.
    Carreno CA, Gadea M (2007) Case report of a kidney transplant recipient converted to everolimus due to malignancy: resolution of bronchiolitis obliterans organizing pneumonia without everolimus discontinuation. Transplant Proc 39:594–595PubMedCrossRefGoogle Scholar
  15. 15.
    Exposito V, de Prada JA, Gomez-Roman JJ, Gonzalez-Vilchez F, Llano-Cardenal M, Garcia-Camarero T, Fernandez-Valls M, Ruano J, Martin-Duran R (2008) Everolimus-related pulmonary toxicity in heart transplant recipients. J Heart Lung Transplant 27:797–800PubMedCrossRefGoogle Scholar
  16. 16.
    Champion L, Stern M, Israel-Biet D, Mamzer-Bruneel MF, Peraldi MN, Kreis H, Porcher R, Morelon E (2006) Brief communication: sirolimus-associated pneumonitis: 24 cases in renal transplant recipients. Ann Intern Med 144:505–509PubMedGoogle Scholar
  17. 17.
    Duran I, Siu LL, Oza AM, Chung TB, Sturgeon J, Townsley CA, Pond GR, Seymour L, Niroumand M (2006) Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. Eur J Cancer 42:1875–1880PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Justine Frija
    • 1
  • Dominique Joly
    • 2
  • Bertrand Knebelmann
    • 2
  • Daniel Dusser
    • 1
  • Pierre-Régis Burgel
    • 1
  1. 1.Service de Pneumologie, Hôpital Cochin, Assistance Publique-Hôpitaux de ParisUniversité Paris-DescartesParis Cedex 14France
  2. 2.Service de Néphrologie, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de ParisUniversité Paris-DescartesParisFrance

Personalised recommendations